94 related articles for article (PubMed ID: 35254868)
1. Administration of Immune Checkpoint Inhibitors Near the End of Life.
Bloom MD; Saker H; Glisch C; Ramnaraign B; George TJ; Markham MJ; Kelkar AH
JCO Oncol Pract; 2022 Jun; 18(6):e849-e856. PubMed ID: 35254868
[TBL] [Abstract][Full Text] [Related]
2. Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life.
Hiramoto S; Taniyama T; Kikuchi A; Hori T; Yoshioka A; Inoue A
Palliat Support Care; 2021 Dec; 19(6):709-714. PubMed ID: 33729120
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitor Use Near the End of Life: A Single-Center Retrospective Study.
Glisch C; Saeidzadeh S; Snyders T; Gilbertson-White S; Hagiwara Y; Lyckholm L
J Palliat Med; 2020 Jul; 23(7):977-979. PubMed ID: 31702481
[No Abstract] [Full Text] [Related]
4. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Immune Checkpoint Inhibitor Administration in Hospitalized Patients With Solid Tumor Malignancies.
Patel AK; Duperreault MF; Pandya CJ; Glotzbecker B; Leblebjian H; Simmons J; Dougherty D
JCO Oncol Pract; 2023 Feb; 19(2):e298-e305. PubMed ID: 36409966
[TBL] [Abstract][Full Text] [Related]
6. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F; Gan G; Li F; Davidoff AJ; Adelson KB; Presley CJ; Adamson BJ; Shaw P; Parikh RB; Mamtani R; Gross CP
JCO Oncol Pract; 2020 Nov; 16(11):e1355-e1370. PubMed ID: 32678688
[TBL] [Abstract][Full Text] [Related]
7. High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors.
Chalker C; Santana-Davila R; Voutsinas JM; Wu QV; Hwang V; Baik CS; Lee S; Barber B; Futran ND; Houlton JJ; Laramore GE; Liao JJ; Parvathaneni U; Martins RG; Eaton KD; Rodriguez CP
J Palliat Med; 2022 Apr; 25(4):614-619. PubMed ID: 34847733
[No Abstract] [Full Text] [Related]
8. Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.
Meyers DE; Pasternak M; Dolter S; Grosjean HAI; Lim CA; Stukalin I; Goutam S; Navani V; Heng DYC; Cheung WY; Morris DG; Pabani A
JTO Clin Res Rep; 2023 Apr; 4(4):100482. PubMed ID: 37090101
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
Durbin SM; Zubiri L; Niemierko A; Bardia A; Sullivan RJ; McEwen C; Mulvey TM; Allen IM; Lawrence DP; Cohen JV; Hochberg EP; Ryan DP; Petrillo LA; Reynolds KL
Oncologist; 2021 Jan; 26(1):49-55. PubMed ID: 33044765
[TBL] [Abstract][Full Text] [Related]
10. Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors.
Krishnan M; Kasinath P; High R; Yu F; Teply BA
JCO Oncol Pract; 2022 Jan; 18(1):e175-e182. PubMed ID: 34351819
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors.
Grad RN; Jung S; Ye F; Sun L; Johnson DB; Agarwal R
Oncologist; 2023 Oct; 28(10):911-916. PubMed ID: 37543031
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors and Palliative Care at the End of Life: An Irish Multicentre Retrospective Study.
O'Sullivan HM; Conroy M; Power DG; Bambury RM; O'Mahony D; Collins DC; O'Leary MJ; O'Reilly S
J Palliat Care; 2022 Feb; ():8258597221078391. PubMed ID: 35129002
[No Abstract] [Full Text] [Related]
15. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
[No Abstract] [Full Text] [Related]
16. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors.
Guven DC; Sahin TK; Aksun MS; Taban H; Aktepe OH; Aksu NM; Akkaş M; Erman M; Kilickap S; Dizdar O; Aksoy S
Support Care Cancer; 2021 Apr; 29(4):2029-2035. PubMed ID: 32851486
[TBL] [Abstract][Full Text] [Related]
17. Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors.
Welaya K; Loh KP; Messing S; Szuba E; Magnuson A; Mohile SG; Maggiore RJ
J Geriatr Oncol; 2020 Apr; 11(3):523-528. PubMed ID: 31175042
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with the initiation of chemotherapy within 90 days of death in metastatic colorectal cancer patients: a population-based study.
Batra A; McKinnon G; Billawala A; Sheka D; Kong S; Cheung WY
Support Care Cancer; 2021 Mar; 29(3):1535-1542. PubMed ID: 32725376
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
20. Symptoms, symptom clusters and associated factors among cancer patients receiving immune checkpoint inhibitor therapy: A cross-sectional survey.
Feng LN; He J; Feng LX; Li Y; Li J; Chen C
Eur J Oncol Nurs; 2023 Apr; 63():102288. PubMed ID: 36893574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]